Treating BPH
Podcast Series
EPISODES - SERIES 1
Episode 6: Patient Centricity with High-Risk BPH Patients
Dr G. Muir & Dr F. Kum
Dr Muir shares his definition of high-risk patients like the elderly, those with large prostates, cardiac problems, or those on anticoagulant treatment. He discusses different recommendations for treatment options regarding this patient group like HoLEP, or GreenLEP. When treating high risk BPH patients, safety is paramount for Dr Muir, and that's also why he considers a good post operative follow up and network for these patients as key success factor in mid-, and long term treatment outcome. Dr Muir shares his recommendations in how to manage long term urethral cathterisation, intermittent self catheterisation, and catheter removal.
This podcast material is for informational purposes only and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health. This podcast was produced in cooperation with Dr Muir and Dr Kum. Results from case studies are not predictive of results in other cases. Results in other cases may vary.Subscribe and listen on
|
|
Click here to sign up for the next podcasts
Episode 5: Role of the Patient in BPH Therapy Selection Process
Dr N. Coull & Dr M. Johnston
Dr Coull from the Kingston Hospital, UK, shares her pathway considerations for male lower urinary tract symptoms (LUTS) and how to best deal with increasingly well-informed patients who often turn to media, social media, friends and patient groups for information and advice regarding treatment options. With the availability of newer minimally invasive procedures, Dr Coull believes that thorough communication with eligible patients regarding short-, mid- and long-term expectations is an important part of providing quality care.
This podcast material is for informational purposes only and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health. This podcast was produced in cooperation with Dr Coull and Dr Johnston. Results from case studies are not predictive of results in other cases. Results in other cases may vary.Subscribe and listen on
|
|
|
Click here to sign up for the next podcasts
Episode 4: BPH Treatment Considerations for High-Risk Patients
Dr H. Cash & Dr M. Kosiba
How to define high risk patients? What treatment options exist for these patients and how to decide which one is the most adapted? In the 4th episode of our BPH podcast series, Dr Hannes Cash, Berlin, gives his point of view and shares his clinical experience. Dr Cash describes how he usually checks the patients’ situation and comorbidities but also the important role played by the anaesthesist . “The decisive factor, I think, is what I then do, which is really to seek discussion and dialogue with the anaesthesist, to clarify in advance whether the patient is at all capable of being anaesthetized.”
PD Dr Hannes Cash
Berlin, Germany
Studied in Germany & Canada
Dr Marina Kosiba
Frankfurt, Germany
Studied in Germany & Canada
Click here to sign up for the next podcasts
Episode 3: Role of the Patient in the BPH Treatment Selection Process
Dr J. Ebbing & Dr M. Kosiba
In the third episode of our BPH podcast series, Dr Ebbing, Basel, explains how his centre offers a patient-centric therapy approach, taking into consideration the individual needs of the patients. Patients with BPH, today, as he observes, are more informed about available treatment options. “These are, for example, men who have the desire for sexual function preservation, namely the younger, sexually active men, who then ask for a procedure to preserve ejaculation."
Dr Jan Ebbing
University Hospital, Basel, Switzerland
Studied in Germany & Australia
Dr Marina Kosiba
Frankfurt, Germany
Studied in Germany & Canada
Click here to sign up for the next podcasts
Episode 2: Challenges and Opportunities for Patients in the Post-COVID Era
Dr K. Saeb-Parsy & Dr F. Kum
Dr Saeb-Parsy, Cambridge, highlights the impact of the COVID pandemic on waiting lists for patients with lower urinary tract symptoms (LUTS). In the second episode of the BPH podcast series, he explores implemented solutions and considerations for categorizing patients based on urgency. Addressing the backlog, he emphasizes the need for smart and efficient approaches while prioritising patient safety. Dr Saeb-Parsy highlights the importance of understanding patients' post-procedure goals for quality of life and providing comprehensive advice to manage expectations.
This podcast material is for informational purposes only and and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health.This podcast was produced in cooperation with Mr Saeb-Parsy and Mrs Kum. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
Subscribe and listen on
|
|
|
Click here to sign up for the next podcasts
Episode 1 | What Do Patients Want?
Dr M. Margreiter & Dr M. Kosiba
What are the primary concerns of patients with BPH when they arrive at your practice? What are the patient selection criteria for Rezūm™ Water Vapour Therapy, and how do you recommend guiding patients towards the most suitable option? How do you explain and prepare eligible patients for Rezūm™ Water Vapour Therapy?
Additionally, what pre- and postoperative elements should patients be aware of? Dr Markus Margreiter addresses these and many other questions regarding the treatment of Benign Prostate Hyperplasia (BPH) and patient communication in this exclusive first podcast episode.
PD Dr Markus Margreiter, USMLE, FEBU, FECMS
Vienna, Austria
Studied in Austria, USA & Germany
Dr Marina Kosiba
Frankfurt, Germany
Studied in Germany & Canada
Click here to sign up for the next podcasts
1. Ajib K, Mansour M, Zanaty M, et al. Photoselective vaporization of the prostate with the 180-W XPS Greenlightlaser: Five-year experience of safety, efficiency and functional outcomes. Can Urol Assoc J. 2018;12(7):E318–E324.
2. Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol. 2011;186(5):1972–1976.
3. Calves J, Thoulouzan M, Perrouin-Verbe MA, et al. Long-Term Patient-Reported Clinical Outcomes and Reoperation Rate After Photovaporization with the XPS-180W GreenLight Laser. Eur Urol Focus. 2019;5(4):676–680.
4. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171–179.
5. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021:206(3):715–724.
6. NICE Guidance. https://www.nice.org.uk/guidance/mtg74. Accessed in July 2023.
7. Sohn JH, Choi YS, Kim SJ, Effectiveness and safety of photoselective vaporization of the prostate with the 120 W HPS Green-Light laser in benign prostatic hyperplasia patients taking oral anticoagulants. Korean J Urol. 2011 Mar;52(3):178-83.
8. McVary KT, El-Arabi A, Roehrborn C. Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia. Sex Med. 2021 Oct 30;9(6):100454.
9. Tallman CT, Zantek PF, Hernandez N, et al. Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison. World J Urol. 2021 Sep;39(9):3207-1
10. Neeser K, Chughtai B, Rojanasarot S, et al. Cost-effectiveness of Convective Water Vapor Energy Therapy Compared to Prostatic Urethral Lift for Treatment of Benign Prostatic Hyperplasia. Presented at ISPOR Europe 2019. Copenhagen, Denmark. November 2-6, 2019.
11. Woo et al. Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (I 80 ml). European Urology Supplements 7: 378–383, 2008.
12. Thomas JA, Tubaro A, Barber N, et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016 Jan;69(1):94-102.
13. Rajih E, Tholomier C, Hueber PA, et al. Evaluation of surgical outcomes with photoselective GreenLight XPS laser vaporization of the prostate in high medical risk men with benign prostatic enlargement: a multicenter study. J Endourol. 2017 Jul;31(7):686-93.
14. Bachmann A, Tubaro A, Barber N, et al. 180W XPS GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomized Trial – The GOLIATH Study. Euro Urol May 2014; 65(5): 931-942.
15. Tan AH, Gilling PJ, Kennett KM, et al. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003:170(4 Pt 1):1270–1274.
16. Data on file with Boston Scientific: AMS™ GreenLight XPS™ Laser System System Operator’s Manual: Indications for Use.
17. Bajic P, et al., A Simplified Technique for GreenLight Laser Enucleation of the Prostate, Urology. 2019 Jan;123:293-294. doi: 10.1016/j.urology.2018.09.031. Epub 2018 Oct 9.
18. Gravas S (Chair), Cornu JN, Drake MJ, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guidelines Office, Arnhem, The Netherlands. 2022. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts [Accessed April 2022].
19. Robert G, Cornu JN, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR, Vicaut E, Lukacs B. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016 Mar;117(3):495-9. doi: 10.1111/bju.13124. Epub 2015 Aug 22. PMID: 25781490.
20. Kampantais S, Dimopoulos P, Tasleem A, Acher P, Gordon K, Young A. Assessing the Learning Curve of Holmium Laser Enucleation of Prostate (HoLEP). A Systematic Review. Urology. 2018 Oct;120:9-22. doi: 10.1016/j.urology.2018.06.012. Epub 2018 Jul 4. PMID: 30403609.
21. Aho T, Herrmann TR. Description of a modular mentorship programme for holmium laser enucleation of the prostate. World J Urol. 2015 Apr;33(4):497-502. doi: 10.1007/s00345-014-1407-1. Epub 2014 Oct 1. PMID: 25271105.
22. Wollin TA, Denstedt JD. The holmium laser in urology. J Clin Laser Med Surg. 1998 Feb;16(1):13-20. doi: 10.1089/clm.1998.16.13. PMID: 9728125.
23. Ramadhani MZ, Kloping YP, Rahman IA, Yogiswara N, Renaldo J, Wirjopranoto S. Comparative efficacy and safety of holmium laser enucleation of the prostate (HoLEP) using moses technology and standard HoLEP: A systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond). 2022 Aug 12;81:104280. doi: 10.1016/j.amsu.2022.104280. PMID: 36147079; PMCID: PMC9486436.
24. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan March 2023. ISBN 978-94-92671-19-6.
25. AUA Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol. 2023;10.1097/JU.0000000000003698. https://doi.org/10.1097/JU.0000000000003698
26. Shah HN, Sodha HS, Kharodawala SJ, Khandkar AA, Hegde SS, Bansal MB. Influence of prostate size on the outcome of holmium laser enucleation of the prostate. BJU Int. 2008 Jun;101(12):1536-41. doi: 10.1111/j.1464-410X.2007.07434.x. Epub 2008 Jan 24. PMID: 18218057.
27. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008 Jan;53(1):160-6. doi: 10.1016/j.eururo.2007.08.036. Epub 2007 Aug 28. PMID: 17869409.
28. Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG. Metaanalysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010 Sep;58(3):384-97. doi: 10.1016/j.eururo.2010.06.005. Epub 2010 Jun 11. PMID: 20825758.
29. Nam JK, Kim HW, Lee DH, Han JY, Lee JZ, Park SW. Risk Factors for Transient Urinary Incontinence after Holmium Laser Enucleation of the Prostate. World J Mens Health. 2015 Aug;33(2):88-94. doi: 10.5534/wjmh.2015.33.2.88. Epub 2015 Aug 19. PMID: 26331125; PMCID: PMC4550601.
30. El‐Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int. 2002 Dec;90(9):863‐9. US and EU (excluding France) 05/22 Clinical Large T, Nottingham C, Stoughton C, et al. Com